195 related articles for article (PubMed ID: 37633912)
1. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.
Nuesslein-Hildesheim B; Ferrero E; Schmid C; Huck C; Smith P; Tisserand S; Rubert J; Bornancin F; Eichlisberger D; Cenni B
J Neuroinflammation; 2023 Aug; 20(1):194. PubMed ID: 37633912
[TBL] [Abstract][Full Text] [Related]
2. Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination.
Evonuk KS; Wang S; Mattie J; Cracchiolo CJ; Mager R; Ferenčić Ž; Sprague E; Carrier B; Schofield K; Martinez E; Stewart Z; Petrosino T; Johnson GA; Yusuf I; Plaisted W; Naiman Z; Delp T; Carter L; Marušić S
Acta Neuropathol Commun; 2023 Jul; 11(1):115. PubMed ID: 37438842
[TBL] [Abstract][Full Text] [Related]
3. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.
Kaul M; End P; Cabanski M; Schuhler C; Jakab A; Kistowska M; Kinhikar A; Maiolica A; Sinn A; Fuhr R; Cenni B
Clin Transl Sci; 2021 Sep; 14(5):1756-1768. PubMed ID: 33834628
[TBL] [Abstract][Full Text] [Related]
4. MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response.
Pellerin K; Rubino SJ; Burns JC; Smith BA; McCarl CA; Zhu J; Jandreski L; Cullen P; Carlile TM; Li A; Rebollar JV; Sybulski J; Reynolds TL; Zhang B; Basile R; Tang H; Harp CP; Pellerin A; Silbereis J; Franchimont N; Cahir-McFarland E; Ransohoff RM; Cameron TO; Mingueneau M
Brain; 2021 Sep; 144(8):2361-2374. PubMed ID: 34145876
[TBL] [Abstract][Full Text] [Related]
5. Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and
Duan R; Goldmann L; Brandl R; Spannagl M; Weber C; Siess W; von Hundelshausen P
Front Cardiovasc Med; 2021; 8():749022. PubMed ID: 34631841
[No Abstract] [Full Text] [Related]
6. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
[TBL] [Abstract][Full Text] [Related]
7. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic stimulation leads B-cell infiltration into the central nervous system upon autoimmunity.
Prado C; Osorio-Barrios F; Falcón P; Espinoza A; Saez JJ; Yuseff MI; Pacheco R
J Neuroinflammation; 2021 Dec; 18(1):292. PubMed ID: 34920747
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
[TBL] [Abstract][Full Text] [Related]
10. Targeting the RNA-Binding Protein HuR Alleviates Neuroinflammation in Experimental Autoimmune Encephalomyelitis: Potential Therapy for Multiple Sclerosis.
Borgonetti V; Sanna MD; Lucarini L; Galeotti N
Neurotherapeutics; 2021 Jan; 18(1):412-429. PubMed ID: 33200288
[TBL] [Abstract][Full Text] [Related]
11. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis.
Tietz S; Périnat T; Greene G; Enzmann G; Deutsch U; Adams R; Imhof B; Aurrand-Lions M; Engelhardt B
Brain Behav Immun; 2018 Oct; 73():3-20. PubMed ID: 29920328
[TBL] [Abstract][Full Text] [Related]
12. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.
Geladaris A; Torke S; Saberi D; Alankus YB; Streit F; Zechel S; Stadelmann-Nessler C; Fischer A; Boschert U; Häusler D; Weber MS
Acta Neuropathol; 2024 Apr; 147(1):75. PubMed ID: 38656399
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice.
Pol S; Liang S; Schweser F; Dhanraj R; Schubart A; Preda M; Sveinsson M; Ramasamy DP; Dwyer MG; Weckbecker G; Zivadinov R
Exp Neurol; 2021 Jan; 335():113488. PubMed ID: 32991933
[TBL] [Abstract][Full Text] [Related]
14. Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis.
Tremolanti C; Cavallini C; Meyer L; Klein C; Da Pozzo E; Costa B; Germelli L; Taliani S; Patte-Mensah C; Mensah-Nyagan AG
Mol Neurobiol; 2022 Mar; 59(3):1744-1765. PubMed ID: 35018577
[TBL] [Abstract][Full Text] [Related]
15. Mannan-MOG35-55 Reverses Experimental Autoimmune Encephalomyelitis, Inducing a Peripheral Type 2 Myeloid Response, Reducing CNS Inflammation, and Preserving Axons in Spinal Cord Lesions.
Dagkonaki A; Avloniti M; Evangelidou M; Papazian I; Kanistras I; Tseveleki V; Lampros F; Tselios T; Jensen LT; Möbius W; Ruhwedel T; Androutsou ME; Matsoukas J; Anagnostouli M; Lassmann H; Probert L
Front Immunol; 2020; 11():575451. PubMed ID: 33329540
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of the total saponin from Panax Japonicus on experimental autoimmune encephalomyelitis by attenuating inflammation and regulating gut microbiota in mice.
Wang J; He L; Wang S; Zhao H; Chen J; Dong Y; Yasen S; Wang L; Zou H
J Ethnopharmacol; 2023 Oct; 315():116681. PubMed ID: 37230280
[TBL] [Abstract][Full Text] [Related]
17. IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis.
Desu HL; Plastini M; Illiano P; Bramlett HM; Dietrich WD; de Rivero Vaccari JP; Brambilla R; Keane RW
J Neuroinflammation; 2020 May; 17(1):143. PubMed ID: 32366256
[TBL] [Abstract][Full Text] [Related]
18. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
Geladaris A; Torke S; Weber MS
CNS Drugs; 2022 Oct; 36(10):1019-1030. PubMed ID: 36178589
[TBL] [Abstract][Full Text] [Related]
19. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.
Weber MS; Prod'homme T; Patarroyo JC; Molnarfi N; Karnezis T; Lehmann-Horn K; Danilenko DM; Eastham-Anderson J; Slavin AJ; Linington C; Bernard CC; Martin F; Zamvil SS
Ann Neurol; 2010 Sep; 68(3):369-83. PubMed ID: 20641064
[TBL] [Abstract][Full Text] [Related]
20. Paricalcitol improves experimental autoimmune encephalomyelitis (EAE) by suppressing inflammation via NF-κB signaling.
Zhang D; Qiao L; Fu T
Biomed Pharmacother; 2020 May; 125():109528. PubMed ID: 32106388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
